Delving into the Latest Updates on EG-007 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

EG-007

Target

HERs

Action

antagonists

Mechanism

HERs antagonists(Receptor tyrosine-protein kinase erbB antagonists)

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

Advanced Endometrial CarcinomaEndometrial Carcinoma

Inactive Indication-

Originator Organization

Shenzhen Eglin Pharmaceutical Co., Ltd

Active Organization

Evergreen Therapeutics, Inc

Inactive Organization-

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

This is a Phase 3, multicenter, randomized, open-label trial to evaluate whether EG-007 plus Len+Pem is superior to Len+Pem alone in patients with advanced endometrial cancer (Stage III or IV). This trial will be preceded by a safety lead-in study with up to 28 patients (the safety lead-in is a separate, free-standing protocol).
Approximately 450 patients will be randomized equally (1:1) to receive EG-007 plus Len+Pem or Len+Pem alone. The randomization will be stratified by the following stratification factors:
* Diagnosis Classification (advanced Stage III/IV vs. recurrent endometrial cancer)
* ECOG score at baseline (0 vs 1)
* Geographic region (Asia vs ROW)

Start Date01 Dec 2026

Sponsor / Collaborator

Evergreen Therapeutics, Inc

NCT05106127

/ Not yet recruitingPhase 2

A Phase 2, Open-Label, Safety Lead-In With Long Term Safety Study of EG-007, Added to the Combination of Lenvatinib Plus Pembrolizumab

This is a Phase 2 trial Safety Lead-in trial conducted in 3 cohorts of patients.
A safety lead-in study of the impact of adding the Repurposed Drugs a third agent will be conducted prior to opening enrollment into the compassionate use study. All patients enrolled in the safety lead-in study may continue long-term treatment under this protocol without interruption of dosing.

Start Date01 Aug 2026

Sponsor / Collaborator

Evergreen Therapeutics, Inc

100 Clinical Results associated with EG-007

Login to view more data

100 Translational Medicine associated with EG-007

Login to view more data

100 Patents (Medical) associated with EG-007

Login to view more data

100 Deals associated with EG-007

Login to view more data